In meta‐analyses combining confounder‐adjusted summary results from both cohorts, sclerostin was associated with a higher risk of DM (1.25; 1.12, 1.37) and elevated fasting glucose levels (1.15; 1.04, 1.26) (odds ratio per one SD change in exposure with 95% CI) and lower eGFR (−0.20; −0.38, −0.02) (change in standardized beta per one SD change in exposure with 95% CI) (Fig. 1A–C). Here, SOST is linked to diabetes mellitus.